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The speciﬁc combination for conditioning regimens in hematopoietic stem cell transplantation continues to
be a premier area of focus in research. Although conditioning regimens have signiﬁcantly evolved over time,
obstacles continue to persist, including regimen-related toxicities, graft-versus-host disease, and disease
relapse. Gemcitabine (2’,2’-diﬂuoro 2’-deoxycytidine, dFdC) is a pyrimidine nucleoside analog that distin-
guishes itself from other agents in the class by possessing a favorable pharmacokinetic and cytotoxic proﬁle,
while maintaining acceptable toxicities. Given the desirable properties, gemcitabine has garnered much
attention and been assessed in several conditioning regimens. In this article, we review the pharmacology of
gemcitabine with other nucleoside analogs and report the ﬁndings of pivotal trials conducted in both
autologous and allogeneic transplantation. The positive results suggest a potential future role for gemcitabine
and necessitate the need to conduct studies to further deﬁne its role.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION Recently, clinical studies have successfully incorporated
The use of hematopoietic stem cell transplantation (HSCT)
has evolved over the past 50 years and now represents
a potentially curative therapy for patients worldwide with
various forms of malignant and nonmalignant diseases.
Although the risks associated with HSCT have been signiﬁ-
cantly reduced, obstacles remain with regimen-related tox-
icities (RRT), graft-versus-host disease (GVHD), and disease
relapse. Because of the impact on these various areas, reﬁning
HSCTconditioning regimens continues to be a premier area of
focus. Research has been dedicated to ﬁnding the speciﬁc
combination of chemotherapy agents, total body irradiation,
and targeted therapies to optimize disease control, while also
limiting treatment-related toxicities and GVHD. Advances,
such as optimizing the systemic exposure of certain drugs
through prospective pharmacokinetic-based monitoring,
have aided in reducing toxicities. Incorporating novel agents
into conditioning regimens has helped improve overall
antitumor activity [1-3]. For example, nucleoside analogs
have become a focus of interest, given their broad therapeutic
activity and mild extramedullary toxicities. Although ﬂu-
darabine already has an established role in allogeneic HSCT,
other agents within the class are also showing promise.edgments on page 1388.
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14.04.025gemcitabine into HSCTconditioning regimens. In this review,
wewill discuss the potential role of gemcitabine in HSCT and
summarize the available clinical data.GEMCITABINE PHARMACOLOGY
Gemcitabine (2’,2’-diﬂuoro 2’-deoxycytidine, dFdC) is a
pyrimidine nucleoside analog [4,5]. Althoughmechanistically
similar, gemcitabine distinguishes itself structurally from
cytarabinebyaﬂuorine group substituted at position2’on the
furanose ring (Figure 1). Gemcitabine, like other nucleoside
analogs, requires cellular uptake via nucleoside transporters
and intracellular phosphorylation for activation. Cellular
uptake of the highly lipophilic gemcitabine molecule across
the cell membrane involves speciﬁc nucleoside transport
proteins through both active processes and facilitated diffu-
sion. Speciﬁcally, 2 types of human nucleoside transporters
havebeen identiﬁed: equilibrative (sodium independent) and
concentrative (sodium dependent). Although both trans-
porters are involved in the cellular uptake of gemcitabine, the
bidirectional equilibrative carriers, such as human ENT1, have
been identiﬁed as the primary transport [4,6,7].
Upon cellular uptake, gemcitabine undergoes phosphor-
ylation by deoxycytidine kinase (dCK) to an intermediate
metabolite gemcitabine monophosphate. The presence of
dCK is rate limiting in gemcitabine activation [8,9]. Although
at a much reduced substrate afﬁnity compared with dCK,
thymidine kinase 2 is also thought to play a minor roleTransplantation.
Figure 1. Nucleoside Analog Structures.
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metabolite is then further converted by other nucleotide
kinases to the active metabolites gemcitabine diphosphate
(dFdCDP) and, most importantly, triphosphate (dFdCTP). It is
dFdCTP that is subsequently incorporated into DNA, resulting
in DNA synthesis inhibition (Figure 2) [6-9].
Although the major mechanism through which gemcita-
bine exerts its activity is inhibition of DNA synthesis, it also
exhibits other cytotoxic mechanisms. Other mechanisms
include direct inhibition of DNA polymerase, resulting in
termination of DNA chain elongation; inhibition of ribonu-
cleotide reductase (RNR), leading to reduced competing
deoxyribonucleotide pools necessary for DNA synthesis; and
incorporation into RNA resulting in direct apoptosis [4,5,8,9].
Of these, the inhibition of DNA polymerase and RNA incor-
poration are largely attributed to dFdCTP. In contrast, dFdCDP
is thought to inhibit RNR and the subsequent reduction in
deoxyribonucleotides, particularly deoxycytidine triphos-
phate [8,9]. Furthermore, it has been suggested that gemci-
tabine may also contain cytotoxic activity by inducing
topoisomerase I-mediated DNA strand breaks [4].GEMCITABINE COMPARED WITH OTHER NUCLEOSIDE
ANALOGS
Two major factors determine the clinical activity of
nucleoside analogs: the substrate speciﬁcity for activating
nucleoside kinases and the expression of these enzymes
within the tumor tissues. The content of dCK is several-fold
higher in lymphocytes than in other epithelial cells. TheFigure 2. Intracellular Metabolism of Gemcitabine [6-9]. hNTs indicates hu-
man nucleoside transporters; TK2, thymidine kinase 2; dFdCMP, gemcitabine
monophosphate; CDA, deoxycitidine deaminase; dFdU, 2’2’-diﬂuorodeoxyur-
idine; dCTP, deoxycytidine triphosphate.afﬁnity of dCK is higher for gemcitabine compared with the
other nucleoside analogs, including ﬂudarabine, cytarabine,
and cladribine. This may explain the broader range of clinical
activity seen with gemcitabine compared with the other
nucleoside analogs [8,10-12].
Collectively, the nucleoside analogs share a similar cyto-
toxic mechanism of inhibiting DNA polymerase at the analog
insertion site upon intracellular activation by dCK phos-
phorylation (Table 1) [4,10,13-19]. Compared with cytarabine
and ﬂudarabine, gemcitabine undergoes greater activation to
dFdCDP and dFdCTP because of its higher afﬁnity for dCK
[9,14]. In addition, gemcitabine possesses an additional
cytotoxic mechanism of inhibiting RNR, the major source of
deoxynucleotides normally required for DNA synthesis and
repair [9]. Although the active metabolites of ﬂudarabine and
clofarabine also possess RNR inhibition activity, only dFdCDP
results in an irreversible inhibition (Table 2) [9,14,15]. Spe-
ciﬁcally, in situ assays have identiﬁed the active metabolite
dFdCDP as inducing the subsequent cellular depletion of
deoxynucleotides, resulting in self-potentiation by prefer-
entially incorporating gemcitabine as dFdCTP into DNA
[9,10]. Furthermore, gemcitabine exhibits the unique ability
of “masked” chain termination. This occurs after dFdCTP DNA
incorporation and includes the addition of a single deoxy-
nucleotide by DNA polymerase, predominantly to the 3’ end
of the extending DNA strand. This speciﬁc type of incorpo-
ration leads to the masking of the gemcitabine nucleotide
from normal DNA polymerase 3’ to 5’ proof-reading exonu-
clease activity that normally removes mismatched base pairs
[9,10]. This masking phenomenon is unique to gemcitabine,
as none of the other nucleoside analog possess a similar
mechanism that may help prevent normal DNA polymerase
proofreading activity [9,14].
From a pharmacokinetic (PK) perspective, gemcitabine
also exhibits favorable attributes that further enhance its
mechanisms of action. Similar to clofarabine triphosphate
(Cl-F-ara-ATP), dFdCTP has a slow cellular elimination half-
life exhibiting both monophasic and biphasic properties
(Table 3). At higher cellular concentrations ( 100 mM),
dFdCTP exhibits more biphasic elimination with a prolonged
terminal half-life of 15 to 24 hours as compared with mono-
phasic elimination of 4 to 6 hours in lower cellular concen-
trations [4,10,13-19]. This unique property of gemcitabine
aids in the self-potentiating mechanism by reducing the
elimination and further promoting the accumulation of the
active metabolite. Speciﬁcally, dFdCTP is thought to reduce
elimination by blocking deoxycytidylate monophosphate
deaminase, its key catabolic enzyme. By blocking deoxy-
cytidylate monophosphate deaminase, the elimination half-
life changes from a monophasic to biphasic elimination,
resulting in higher cellular dFdCTP concentrations, further
enhancing the cytotoxic activity of gemcitabine [14].
Parental gemcitabine at high intracellular levels acts as a
substrate inhibitor of dCK, thus explaining that levels of
dFdCTP peak with intracellular gemcitabine levels of around
20 mmol/L [8,10,11]. In addition to inherent PK advantages,
infusion times of gemcitabine have a direct effect on the ac-
tivity of gemcitabine. Prolonged infusions at a ﬁxed-dosed
rate (FDR) of 10 mg/m2/minute avoid the saturation of dCK
activity by maintaining extracellular gemcitabine concentra-
tions below 15 to 20 mM [20-22]. This FDR strategy has
resulted in increased concentration-time curves of dFdCTP in
leukemic cells as compared with the standard infusion times
[8,23]. Furthermore, DNA synthesis remains suppressed up to
24 hours after the initiation of the gemcitabine infusion [24].
Table 1
Nucleoside Analog Comparison: Mechanism of Action [4,10,13-19]
Comparison Gemcitabine Cytarabine (Ara-C) Fludarabine Clofarabine
Chemotherapy class Pyrimidine analogs Purine analogs
Mechanisms of action
Inhibition of DNA polymerase Intermediate Strong Strong Strong
Inhibition of DNA chain elongation Intermediate Strong Strong Strong
Inhibition of RNA synthesis Weak Weak Strong Weak
Other  Masked DNA chain
termination
-  Prevents DNA ligation  Induces apoptosis




 Triphosphate (F-ara-ATP)  Triphosphate (Cl-F-ara-ATP)
 Monophosphate (Cl-F-ara-A)
Ara-CTP indicates cytarabine triphosphate; F-ara-ATP, ﬂudarbine triphosphate; Cl-F-ara-ATP, clofarabine triphosphate; Cl-F-ara-A, clofarabine
monophosphate.
E. Wang et al. / Biol Blood Marrow Transplant 20 (2014) 1382e13891384Although more active in certain malignancies, FDR adminis-
tration also results in increasedmyelosuppression and limited
nonhematologic toxicities, such as elevations of trans-
aminases [25-28]. The increased toxicities with gemcitabine
FDR infusions have prevented its widespread use in oncology
practice, instead favoring the shorter 30-minute infusion,
despite the PK and pharmacodynamic advantages of FDR.
GEMCITABINE ACTIVITY
In addition to its broad use for solid malignancies,
gemcitabine has also demonstrated in vitro and clinical
activity in hematologic malignancies, such as leukemia,
non-Hodgkin’s lymphoma (NHL), and Hodgkin’s lymphoma
(HL) [11,12,23,29]. Speciﬁcally, ﬂudarabine and gemcitabine
combinations have demonstrated synergy in phase 1 studies
for relapsed or refractory acute myelogenous leukemia, with
minimally active concentrations of both agents resulting in a
3- to 4-fold increase in activity compared with either agent
alone [29]. Additionally, when combined with traditional
alkylating agents, such as melphalan and busulfan, nucleo-
side analogs are able to inhibit DNA repair of alkylator-
mediated DNA damage [30-32].
GEMCITABINE USE IN AUTOLOGOUS HSCT
Gemcitabine/Docetaxel/Melphalan/Carboplatin
Several gemcitabine-containing conditioning regimens
have been assessed in the autologous HSCT setting. In 1 of
the earlier reports of gemcitabine use by Nieto et al., gem-
citabine at FDR of 10 mg/m2/minute was combined with a
previously described regimen consisting of high-dose doce-
taxel, melphalan, and carboplatin [33]. The length of gem-
citabine infusionwas escalated from 9 to 20 hours (total dose
of 12,000 mg/m2), which was established as its maximum
tolerated dose (MTD) (Figure 3).
A total of 52 heavily pretreated patients with refractory
solid tumors and lymphomas were enrolled. The major
nonhematologic RRT included stomatitis and gastrointestinalTable 2





Metabolite with activity dFdCDP Non
RNR inhibition Irreversible Non
RNR strength of inhibition Potent Non
Afﬁnity for deactivating enzymes
dCMP deaminase Substrate Subs
dCMP indicates deoxycytidylate monophosphate; dCK, deoxycytidine kinase; RN
ﬂudarabine triphosphate; and Cl-F-ara-ATP, clofarabine triphosphate.toxicity (Table 4). Thirty-one of 34 patients (91%) with
measurable disease before HSCT responded to gemcitabine/
docetaxel/melphalan/carboplatin (Gem-DMC), with 50% ex-
periencing a complete response (CR). Median duration of
responsewas 19months (range, 4 to 30þmonths). Atmedian
follow-up time of 24months (range, 13 to 33months), 79% of
patients were alive, with 54% of them remaining disease free.
Median event-free survival (EFS) was 26 months, although
overall survival (OS) had not yet been reached (Table 5) [33].
PK and pharmacodynamic analyses were conducted by
measuringplasmagemcitabine and2’,2’-deoxydiﬂuorouridine
levels, as well as intracellular dFdCTP levels in mononuclear
cells. Gemcitabine exhibited a linear PK behavior at highdoses,
with a linear increase of its area under the curve with the
duration of infusion from 9 to 20 hours (r2 ¼ .71, P < 10-5),
with no major differences observed in clearance (r2 ¼ .005,
P ¼ .60), maximum concentration (P ¼ .14), volume of distri-
bution (P ¼ .95), half-life (P ¼ .85), or steady-state concentra-
tion (P ¼ .37). Serial measurements of intracellular dFdCTP
levels throughout treatment showed an exponential increase
after the last of the 4 daily treatments, consistentwith the self-
potentiating mechanisms of gemcitabine activation [33].
This regimen is also currently being evaluated in other
oncologic venues. Speciﬁcally, Gem-DMC with combination
bevacizumab is being assessed in an ongoing phase 2 trial for
patients with refractory germ-cell tumors (Clinical Trials:
NCT00936936) [34]. Treatment in this phase 2 trial consists
of patients receiving bevacizumab on day -14, followed by 2
different high-dose chemotherapy (HDC) regimens initiated
on day -5 with stem-cell support on day 0. The 2 HDC regi-
mens consist of Gem-DMC as conditioning for the ﬁrst HSCT,
followed by ifosfamide/carboplatin/etoposide for the second
HSCT. In the preliminary analysis of the ﬁrst 21 patients,
tumor markers normalized in 14 of 17 evaluable patients
after HDC cycle 1. Mucositis was the most common toxicity.
At a median follow-up time of 23 months (range, 3 to 43






R, ribonucleotide reductase; dFdCDP, gemcitabine diphosphate; F-ara-ATP,
Table 3
Nucleoside Analog Comparison: Pharmacokinetics [4,10,13-19]
Comparison Gemcitabine Cytarabine (Ara-C) Fludarabine Clofarabine
Triphosphate cellular elimination Slow Rapid N/A Slow
Elimination half-life Monophasic: 4-6 h
Biphasic*: 15-24 h
Biphasic:
a half-life: 7-20 min
b half-life: 2-3 h
Monophasic: 15- <24 h Triphasic:
b half-life: 8-24 h
g half-life: >24 h
Self-potentiation Yes No Yes Yes
* At higher cellular concentrations  100 mM
E. Wang et al. / Biol Blood Marrow Transplant 20 (2014) 1382e1389 1385Gemcitabine/Busulfan/Melphalan
Although the BEAM (carmustine [BCNU], etoposide,
cytarabine, and melphalan) regimen has long been consid-
ered 1 of the standard HDC regimens utilized before autol-
ogous HSCT for patients with chemosensitive relapsed HL
and diffuse large B cell lymphoma, relapse remains a major
concern [10,36]. Patients with primary refractory tumors or
high-risk relapse, such as those whose tumors relapsewithin
1 year, are at a particularly higher risk for relapse after BEAM.
Inpreclinical studies, exposureof chemotherapy-refractory
T and B cell lines individually to gemcitabine, busulfan, and
melphalan resulted inno signiﬁcant effect on cell proliferation.
Variations of 2-drug combinations (busulfan/melphalan,
gemcitabine/busulfan, and gemcitabine/melphalan) led to
mean inhibition of proliferation rates of 16%, 18%, and 22%,
respectively. In contrast, exposure to triple therapy with
gemcitabine, busulfan, andmelphalan (Gem/Bu/Mel) led to an
average inhibition of proliferation rate of 48%, signiﬁcantly
greater than any of the 2-drug combinations (P < .001) [10].
These preclinical observations led to a dose- and schedule-
ﬁnding study of Gem/Bu/Mel, where 3 different schedules of
gemcitabinewere assessed in combinationwith busulfan and
melphalan in 133 patients with refractory lymphoid malig-
nancies, including HL, NHL, and myeloma. Gemcitabine was
infused daily for 6 days on days -8 to -5 and -3 to -2; as 3 doses
on days -8, -6, and -3; or as 2 doses on days -8 and -3
(Figure 4). Each dose of gemcitabinewas administeredwith a
loading dose of 75 mg/m2 i.v. bolus, targeting a steady-state
concentration of 15 mmol/L, followed by FDR of gemcitabine,
followed by the corresponding doses of busulfan and/or
melphalan [10].
The cutaneous and mucosal toxicity proﬁle of Gem/Bu/
Mel was more pronounced with the daily 6-dose and 3-dose
gemcitabine schedules, whereas the 2-dose gemcitabine
schedule resulted in a much ameliorated proﬁle of mucositis,Figure 3. Treatmentrash, and self-limited asymptomatic transaminase elevation
(Table 6). Following the 2-dose gemcitabine schedule, doses
were escalated from level 1 to 9, with level 9 established as
the MTD (daily dose of 2775 mg/m2 and total dose of 5550
mg/m2).
Response rates among HL patients were 88%, with 62%
of patients in CR. At a median follow-up of 24months (range,
3 to 63 months), the EFS and OS rates were 54% (44 of 80
patients) and 72% (58 of 80 patients), respectively, with a
median EFS of 43 months and median OS not reached
(Table 5) [10]. The high antitumor activity of Gem/Bu/Mel in
HL raises the question of how it compares with current
standard HDC regimens.
In a contemporary cohort study of all patients with
refractory or high-risk relapsed HL who underwent trans-
plantation at MD Anderson between 2005 and 2010, Gem/
Bu/Mel, BEAM, and busulfan/melphalan (Bu/Mel) were
compared [36]. A total of 180 patients were analyzed, 84 of
whom received Gem/Bu/Mel, 39 received Bu Mel, and 57
received BEAM. Of all patients treated, 86 patients and 94
patients were primary refractory and poor-risk relapsed
patients, respectively. Of note, the Gem/Bu/Mel arm included
signiﬁcantly more patients with primary refractory disease
and other poor prognostic features, such as positron emis-
sion tomography (PET)epositive tumors and tumor growth
at time of HDC, as well as extranodal disease and bulky
tumors (> 5 centimeters) at relapse or progressive disease.
Themedian follow-up times were 32months (range,12 to
68 months), 36 months (range, 3 to 72 months), and 49
months (range, 8 to 66 months) for the Gem/Bu/Mel, Bu/Mel,
and BEAM cohorts, respectively. The Bu/Mel and BEAM
groups had similar EFS rates (33% versus 39%, P ¼ .60).
Despite having worse prognostic features, the Gem/Bu/Mel
cohort had signiﬁcantly improved EFS rates when compared
with the combined EFS rates of Bu/Mel and BEAM groupsRegimen [33].
Table 4
Gem-DMC Toxicities [33]*





Grade I-II 22 (44.2) - -
Grade III-IV - - -
Diarrhea
Grade I-II 9 (17.3) Day þ14 -
Grade III-IV 4 (7.7) -
Enterocolitis
Grade I-II 2 (3.8) - 5
Grade III-IV 4 (7.7) -
Erythematous Rashes
Grade I-II 5 (9.6) - -
Grade III-IV 2 (3.9) - -
Mucositis
Grade I-II 24 (46.2) Day þ2 4
Grade III-IV 14 (26.9)
Myoarthralgia
Grade I-II 29 (55.8) Day 3 2
Grade III-IV - - -
Onycholysis
Grade I-II 12 (23.1) - -
Grade III-IV - - -
Peripheral neuropathy
Grade I-II 13 (25) - -
Grade III-IV - - -
Gemcitabine MTD 9 (17.3) - -
Transaminitis
Grade I-II 16 (30.8) Day 3 7
Grade III-IV 9 (17.3)
* As reported in  5% of the study population.
E. Wang et al. / Biol Blood Marrow Transplant 20 (2014) 1382e13891386(57% versus 35%, P ¼ .01). The median EFS times were not
reached for Gem/Bu/Mel andwere 13months and 12months
for Bu/Mel and BEAM, respectively. As for OS, the rates for the
Gem/Bu/Mel, Bu/Mel, and BEAM groups were 82%, 52%, and
59%, respectively, with median OS times not reached for
Gem/Bu/Mel, and 63 months and 53 months for Bu/Mel
and BEAM, respectively (Table 5). Gem/Bu/Mel resulted in
improved OS compared with the combined Bu/Mel and
BEAM groups (82% versus 54%, P ¼ .04) [36].
Furthermore, in the speciﬁc analyses of the Gem/Bu/Mel
subgroup, negative PET status at the time of HDC, history of
only receiving 1 prior salvage therapy, gemcitabine naïve
patients, and disease status all signiﬁcantly correlated withTable 5













Gem-DMC [33] All 52 - - - 54 79
Gem/Bu/Mel [10] B-DLCL 17 88 - 60 - -
HL 41 88 - 62 54 72
Gem/Bu/Mel [36] HL 84 91 - 74 57 82
Bu/Mel [36] HL 39 67 - 58 33 52
BEAM [36] HL 57 88 - 56 39 59
Gem/Bu/Mel [37] B-DLCL 30 - 100 69 80 83
Burkitt’s 3 - 100 100 -* -*
FL 2 - 100 100 -y -y
T-NHL 11 - 66 66 73 73
GN-CyBV [40] HL 92 - - - 67 83
Gem-BM [41] HL/T-NHL 22 - - - 70 85
NHL 33 - - - 30 35
G-FM [42] HL 15 - - - 49 87
RR indicates response rate; ORR, overall response rate; CR, complete
response; EFS, event free survival; OS, overall survival; A, cytarabine; B ¼
BCNU, carmustine; BU, busulfan; C, carboplatin; Cy, cyclophosphamide; D,
docetaxel; E ¼ V, etoposide; F, ﬂudarabine; G or Gem, gemcitabine; M or
Mel, melphalan; N, vinorelbine.
* All 3 patients relapsed at 3 months and passed.
y One patient in CR and 1 patient alive with relapsed disease.better EFS. Speciﬁcally, the difference in EFS between the CR2
and CR3 patients approached signiﬁcance (P ¼ .06), whereas
the difference betweenPR2 and CR3 patients did not (P¼ .90).
This cohort study suggests improved clinical outcomes with
Gem/Bu/Mel in primary refractory or poor-prognosis
relapsed HL patients as compared with the 2 other treat-
ment cohorts [36].
The NHL subgroup included 46 patients, of which 22
patients and 24 patients had primary refractory and poor-
risk relapsed disease, respectively. Thirty patients had
diffuse large-cell lymphoma (DLCL), 3 patients had Burkitt’s
lymphoma, 2 patients had follicular lymphoma, and 11 pa-
tients had T cell NHL (T-NHL) [37]. They had experienced
multiple prior relapses ( 1 in 17 patients,>1 in 29 patients),
had a secondary International Prognostic Index score at
relapse/progressive disease of 0 to 1 in 7 patients and > 1
in 33 patients, high lactate dehydrogenase at relapse/pro-
gressive disease (13 patients), and 50% had a positive PET at
the time of HDC. At a median follow-up time of 16 months
(range, 2 to 57 months), the EFS rates were 80% and 73% for B
cell DLCL (B-DLCL) and T-NHL, respectively (Table 5). The OS
rates were 83% and 73% for B-DLCL and T-NHL, respectively.
This subgroup analysis suggests that Gem/Bu/Mel has high
clinical activity in refractory or poor-risk relapsed NHL [37].
The above study demonstrated that high doses of FDR
gemcitabine can be safely combined with Bu/Mel for autol-
ogous HSCTwith encouraging signs of high activity in HL and
NHL. A phase 2 trial is currently underway at MDAnderson to
conﬁrm these results with Gem/Bu/Mel in refractory HL
patients [38]. A separate phase 2 trial in refractory myeloma
patients has recently completed accrual [39].
Gemcitabine in Other Autologous HSCT Regimens
Arai et al. from Stanford University reported on the
combination of gemcitabine and vinorelbine to the cyclo-
phosphamide, BCNU, and etoposide regimen in 92 relapsed/
recurrent HL patients. Their goal was to allow for a reduction
in BCNU dose and, therefore, reduce BCNU-associated tox-
icities [40]. A gemcitabine dose of 1250 mg/m2 was deﬁned
as the MTD. Of note, 85 patients (92%) underwent trans-
plantation with chemosensitive disease and 58% of patients
(53 patients) were in CR at the time of HDC. The authors
observed a 15% incidence rate (14 patients) of pneumonitis,
seemingly lower than the historical control rate of 35% using
higher doses of BCNU. At a median follow-up time of 29
months (range, 8 to 86 months), the 2-year EFS was 67% (95%
conﬁdence interval [CI] 57% to 77%) and 2-year OS was
83% (95% CI, 75% to 91%) (Table 5) [40].
Furthermore, Rapoport et al. from the University of
Maryland also reported on a modiﬁed BEAM regimen, by
substituting cytarabine and etoposide with gemcitabine in
55 patients with either relapsed/refractory or high-risk NHL
or relapsed/refractory HL. Of the 33 patients in the NHL
subgroup, at the time of transplantation, 12 patients, 14
patients, and 7 patients had relapsed, primary refractory, and
high-risk remission status, respectively. Of the 22 HL and T
cell lymphoma patients at the time of transplantation, 15
patients, 6 patients, and 1 patient had relapsed, primary
refractory, and high-risk remission status, respectively, at the
time of transplantation. The 2-year EFS rates were 70% (95%
CI, 53% to 94%) and 30% (95% CI, 18% to 53%) for the HL/T cell
lymphoma and NHL subgroups, respectively. The 2-year OS
rates were 85% (95% CI, 71% to 100%) and 35% (95% CI, 21%
to 58%) for the HL/T cell lymphoma and NHL subgroups,
respectively (Table 5) [41].
Figure 4. Treatment Regimen [10].
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Gemcitabine/Fludarabine/Melphalan
Gemcitabine has also been studied for inclusion in allo-
geneic HSCT conditioning regimens. Anderlini et al. com-
bined gemcitabine with a standard regimen of ﬂudarabine
andmelphalan in 15 patients with relapsed and refractory HL
[42]. They had received a median of 4 previous therapies
(range, 2 to 9 therapies), including a prior autologous HSCT in
7 patients, with a median time to progressive disease of 10
months (range, 3 to 19 months) after autologous HSCT. At a
median follow-up time of 18months (range, 3 to 33months),
EFS and OS were 49% (95% CI, 18% to 74%) and 87% (95% CI,
56% to 96%), respectively (Table 5) [42].
RRT such as pulmonary toxicity occurred in 4 patients
(26%), cutaneous toxicities in 5 patients (33%), mucositis in
9 patients (60%), and grades II to IV cardiac toxicity in 5
patients (33%). Of note, 1 of 2 patients who received higher-
dosed gemcitabine (1000 mg/m2 for 2 doses) experienced
severe multiorgan toxicities and graft rejection, and thus, the
dosing strategy was no longer pursued [42].Table 6
Gem/Bu/Mel Toxicities [10]





Grade I-II 8 (6.2) - -
Grade III-IV - - -
Erythematous Rashes
Grade I-II 23 (17.8) - -
Grade III-IV 3 (2.3) - -
Mucositis
Grade I-II 75 (58.1) Day þ4 2
Grade III-IV 29 (22.5)
Pneumonitis
Grade I-II 2 (1.6) - -
Grade III-IV - - -
Renal toxicity
Grade I-II 1 (0.8) - -
Grade III-IV - - -
Transaminitis
Grade I-II 97 (75) Day þ1 7
Grade III-IVPreclinical experiments by Valdez et al. have additionally
shown marked synergy of double nucleoside analog combi-
nations, using gemcitabine and clofarabine or ﬂudarabine,
with busulfan [31,32]. These observations have led to ongoing
phase 2 studies of gemcitabine, clofarabine, and busulfan in
allogeneic HSCT for refractory aggressive lymphomas [43]
and chronic lymphocytic leukemia [44], seeking to develop
an active, high-dose, reduced-toxicity conditioning regimen
for this difﬁcult to treat population.
FUTURE DIRECTIONS
In an attempt to further develop Gem/Bu/Mel in the
autologous HSCT setting, the histone deacetylase inhibitor
suberoylanilide hydroxamic acid (SAHA) has been added to
this regimen. The beneﬁt of SAHA is its ability to induce
chromatin structural alterations to further facilitate DNA
access for alkylating agents, such as busulfan and melphalan.
Valdez et al. have tested various combinations of these drugs
in T and B lymphoma cell lines that were previously exposed
to the individual agents of gemcitabine, busulfan, and
melphalan, without signiﬁcant effects on cell proliferation or
proportion of apoptotic cells. Conﬁrming their prior experi-
ments, exposure to triple therapy resulted in 52% inhibition
of proliferation rate and 39% of cells in apoptosis. Further-
more, SAHA increased the cytotoxicity of Gem/Bu/Mel,
increasing inhibition of cell proliferation by 65% [30]. A study
testing the concurrent addition of escalating doses of SAHA
to Gem/Bu/Mel (Clinical Trial: NCT01421173) is approaching
completion [45]. Preliminary analysis conducted on 66
patients who were enrolled between October 2011 and June
2013 suggest a SAHA dose of 1000 mg with Gem/Bu/Mel
without encountering additional dose-limiting toxicities, as
previously reported with Gem/Bu/Mel alone. Preliminary
efﬁcacy results also demonstrated 1-year EFS of 72%, 71%,
and 100% and 1-year OS of 94%, 91%, and 100% in patients
with HL, B-DLCL, and T-NHL, respectively [46].
QUESTIONS STILL UNANSWERED
Gemcitabine is a unique nucleoside analog that demon-
strates an additional cytotoxic mechanism of inhibiting ribo-
nucleotide reductase,which results in amaskingphenomenon
E. Wang et al. / Biol Blood Marrow Transplant 20 (2014) 1382e13891388upon dFdCTP DNA incorporation. The addition of this agent to
standard conditioning regimens such as Bu/Mel has demon-
strated high clinical activity by eliciting higher CR rates in
refractoryorpoor-risk relapsedNHLpatients in the autologous
HSCT setting [10,37].
Taken together, the studies abovehavenotonlyestablished
theefﬁcacyof gemcitabine-containing conditioning regimens,
but also their favorable toxicity proﬁle of self-limiting muco-
sitis, rash, and transient elevations in transaminases [10,33].
Identifying predictive markers for severe toxicity to condi-
tioning regimens and/or outcomes in HSCT candidates would
be beneﬁcial. Analyses of pretransplantation serum ferritin,
C-reactive protein, brain natriuretic peptide, and haptoglobin
have, thus far, failed to show a correlation with the incidence
of severe extramedullary side effects. Ongoing research is
analyzing the correlation of common single nucleotide poly-
morphisms of the most important enzymes involved in the
metabolism of gemcitabine, detoxiﬁcation of busulfan, and
DNA damage repair with toxicity and outcome endpoints.
In summary, gemcitabine is rapidly emerging as a major
agent in HSCT. Phase 2 and, ultimately, phase 3 trial data will
be necessary to further deﬁne the role of gemcitabine com-
binations, particularly, Gem/Bu/Mel, in the management of
these malignancies.
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